Progress on the Lyme Disease Vaccine Sparks Buying Interest!
Valneva is already a market leader with vaccines in niche areas such as Chikungunya!
The Lyme disease vaccine could also become a significant success, making Valneva a potential acquisition target!
Reading Time: 2 minutes
Recently, speculative investors have shown renewed interest in biotechnology stocks on international equity markets due to FDA approval advancements and M&A activities. In this context, the European Valneva SE (i.) could also come back into focus. The biotech already has approved vaccines against Chikungunya, Cholera, and Japanese Encephalitis (JE). Moreover, research is being conducted on vaccines for Shigella, Zika, and Lyme disease. This week, the publication of positive results from the final Phase 2 study for the vaccine candidate against...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
